Invivyd (Invivyd) Cash, Cash Equivalents, Marketable Securities : $189.39 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Invivyd Cash, Cash Equivalents, Marketable Securities?

Invivyd's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($264.89 Mil) to Dec. 2023 ($200.64 Mil) but then stayed the same from Dec. 2023 ($200.64 Mil) to Mar. 2024 ($189.39 Mil).

Invivyd's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($591.42 Mil) to Dec. 2022 ($371.99 Mil) and declined from Dec. 2022 ($371.99 Mil) to Dec. 2023 ($200.64 Mil).

Invivyd Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Invivyd's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invivyd Cash, Cash Equivalents, Marketable Securities Chart

Invivyd Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

114.99

591.42

371.99

200.64

Invivyd Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial										333.43	298.43	264.89	200.64	189.39

Invivyd Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Invivyd (NAS:IVVD) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Invivyd Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Invivyd's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Invivyd (Invivyd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invivyd Inc (NAS:IVVD) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1601 Trapelo Road, Suite 178, Waltham, MA, USA, 02451

Website

https://www.invivyd.com

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Executives

Adimab, Llc	10 percent owner, other: See Remarks	7 LUCENT DRIVE, LEBANON NH 03766
William E. Duke	officer: Chief Financial Officer	C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Sara Cotter	director	1735 MARKET STREET, FLOOR 23, PHILADELPHIA PA 19103
Allen Robert D. Iii	officer: Chief Scientific Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Stacy Price	officer: Chief Tech. and Manuf. Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jeremy Gowler	officer: COO & CCO	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Rebecca Dabora	officer: Chief Tech and Manuf Officer	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Peter Schmidt	officer: Chief Medical Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jill Andersen	officer: Chief Legal Officer, Secretary	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Christine Lindenboom	director	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Frederick W Driscoll	officer: Interim CFO
David Hering	director, officer: Chief Executive Officer	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Marc Elia	director, other: See Remarks	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
M28 Capital Management Lp	other: See Remarks	700 CANAL STREET, 2ND FLOOR, STAMFORD CT 06902
Clive Meanwell	director, 10 percent owner	THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054